DE60231263D1 - Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden - Google Patents

Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden

Info

Publication number
DE60231263D1
DE60231263D1 DE60231263T DE60231263T DE60231263D1 DE 60231263 D1 DE60231263 D1 DE 60231263D1 DE 60231263 T DE60231263 T DE 60231263T DE 60231263 T DE60231263 T DE 60231263T DE 60231263 D1 DE60231263 D1 DE 60231263D1
Authority
DE
Germany
Prior art keywords
nerve
substance
remedy
dendritic cells
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60231263T
Other languages
German (de)
English (en)
Inventor
Masahiro Toda
Yutaka Kawakami
Yoshiaki Toyama
Yuji Mikami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Gene and Brain Science
Original Assignee
Institute of Gene and Brain Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Gene and Brain Science filed Critical Institute of Gene and Brain Science
Application granted granted Critical
Publication of DE60231263D1 publication Critical patent/DE60231263D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60231263T 2001-03-12 2002-03-12 Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden Expired - Fee Related DE60231263D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001069123 2001-03-12
JP2001338772 2001-11-02

Publications (1)

Publication Number Publication Date
DE60231263D1 true DE60231263D1 (de) 2009-04-02

Family

ID=26611082

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60231263T Expired - Fee Related DE60231263D1 (de) 2001-03-12 2002-03-12 Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden
DE60220894T Expired - Fee Related DE60220894T2 (de) 2001-03-12 2002-03-12 Verwendung von interleukin-12 zur behandlung von nervenschäden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60220894T Expired - Fee Related DE60220894T2 (de) 2001-03-12 2002-03-12 Verwendung von interleukin-12 zur behandlung von nervenschäden

Country Status (7)

Country Link
US (2) US20040120925A1 (fr)
EP (2) EP1723969B1 (fr)
JP (1) JP3607271B2 (fr)
AT (2) ATE422901T1 (fr)
CA (1) CA2441434A1 (fr)
DE (2) DE60231263D1 (fr)
WO (1) WO2002072144A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019082B2 (fr) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Utiliastion d'un facteur des colonies (csf) pour augmenter la croissance collaterale des arteres collaterales et/ou d'autres arteres a partir de connexions arteriolaires preexistantes
FR2834898B1 (fr) * 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
JP3984959B2 (ja) * 2002-03-27 2007-10-03 株式会社Ｇｂｓ研究所 神経幹細胞の増殖誘導方法
CA2492542A1 (fr) * 2002-07-30 2004-02-05 Stem Cell Therapeutics Inc. Production d'oligodendrocyte a partir de cellules souches neurales multipotentes
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004058287A2 (fr) * 2002-12-31 2004-07-15 Axaron Bioscience Ag Methodes de traitement d'etats neurologiques faisant appel a des facteurs de croissance hematopoietiques
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7569545B2 (en) * 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬
US20100215722A1 (en) * 2006-02-28 2010-08-26 Vishal Bhasin Tissue Regeneration II
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
EP1994934A4 (fr) 2006-12-05 2010-03-10 Glycoscience Lab Inc Agent thérapeutique pour l'arthrose
WO2013016634A1 (fr) * 2011-07-27 2013-01-31 Neumedicines, Inc. Utilisation d'il-12 pour générer de l'érythropoïétine endogène
CN107148278B (zh) * 2014-08-15 2021-06-29 财团法人卫生研究院 利用神经干细胞与IL12p40增强神经再生的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
JPH05148155A (ja) * 1991-11-28 1993-06-15 Toray Ind Inc 神経栄養薬
JPH05213767A (ja) * 1992-02-07 1993-08-24 Mochida Pharmaceut Co Ltd 脳神経疾患治療剤
EP0599303A3 (fr) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Conjugués peptidiques
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
JPH08176008A (ja) * 1994-12-27 1996-07-09 Toray Ind Inc 神経栄養薬
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US6267955B1 (en) * 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
CA2213906A1 (fr) * 1996-09-23 1998-03-23 Dusica Maysinger Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique
AU8180498A (en) * 1997-06-30 1999-01-19 Regents Of The University Of California, The Method for treatment of spinal cord injuries in a mammal
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法

Also Published As

Publication number Publication date
EP1374898B1 (fr) 2007-06-27
CA2441434A1 (fr) 2002-09-19
ATE365561T1 (de) 2007-07-15
EP1374898A1 (fr) 2004-01-02
EP1723969A1 (fr) 2006-11-22
US20070243160A1 (en) 2007-10-18
WO2002072144A9 (fr) 2002-12-27
EP1374898A4 (fr) 2004-07-28
WO2002072144A1 (fr) 2002-09-19
ATE422901T1 (de) 2009-03-15
JPWO2002072144A1 (ja) 2004-07-02
DE60220894D1 (de) 2007-08-09
JP3607271B2 (ja) 2005-01-05
US20040120925A1 (en) 2004-06-24
DE60220894T2 (de) 2008-02-28
EP1723969B1 (fr) 2009-02-18

Similar Documents

Publication Publication Date Title
DE60231263D1 (de) Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden
Hermann et al. Neural precursor cells in the ischemic brain–integration, cellular crosstalk, and consequences for stroke recovery
Cohen et al. Cell biology of fat storage
Jia et al. Sciatic nerve repair by acellular nerve xenografts implanted with BMSCs in rats xenograft combined with BMSCs
KR102353601B1 (ko) 줄기세포의 면역조절성 효과의 조절 방법
Siddiqui et al. Translating mechanisms of neuroprotection, regeneration, and repair to treatment of spinal cord injury
Boido et al. Mesenchymal stem cell transplantation reduces glial cyst and improves functional outcome after spinal cord compression
Mokarram et al. Effect of modulating macrophage phenotype on peripheral nerve repair
Bunge et al. Transplantation strategies to promote repair of the injured spinal cord.
Novikova et al. Efficacy of olfactory ensheathing cells to support regeneration after spinal cord injury is influenced by method of culture preparation
Gillespie et al. Clinical application of neurotrophic factors: the potential for primary auditory neuron protection
Torres-Espín et al. Immunosuppression of allogenic mesenchymal stem cells transplantation after spinal cord injury improves graft survival and beneficial outcomes
MX9707669A (es) Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido.
ATE201827T1 (de) Methoden und mittel zur förderung der wundheilung
Lucia Maria Ferri et al. Mesenchymal stem cells for ischemic stroke: progress and possibilities
CA2123049A1 (fr) Compose pharmaceutique contenant la sous-unite p40 de l'interleukine 12
Asgharzade et al. A review on stem cell therapy for neuropathic pain
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
Seo et al. Early immunomodulation by intravenously transplanted mesenchymal stem cells promotes functional recovery in spinal cord injured rats
Kumar Das et al. Current status and prospective application of stem cell-based therapies for spinal cord injury
Feng et al. Graft of pre-injured sural nerve promotes regeneration of corticospinal tract and functional recovery in rats with chronic spinal cord injury
Dijkhuizen et al. The use of neurotrophic factors to treat spinal cord injury: advantages and disadvantages of different delivery methods
Tefferi et al. Current perspective in agnogenic myeloid metaplasia
Hirota et al. Local application of a transcutaneous carbon dioxide paste prevents excessive scarring and promotes muscle regeneration in a bupivacaine‐induced rat model of muscle injury
ATE77754T1 (de) Zusammensetzungen zur behandlung von gehirntumoren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee